The strong financial performance and robust cash position support the company’s 2026 outlook and buyback. Traders should monitor upcoming Phase 3 data for REZZAYO in Q2 2026 as a key catalyst.
Price Chart
Executive Summary
CorMedix reported strong Q4 and full-year 2025 results, driven by $128.6M in revenue (up 312% YoY) and $163.1M net income, a turnaround from a $17.9M loss in 2024. Growth was fueled by DefenCath sales and the full-quarter contribution from the Melinta acquisition. The company reiterated 2026 guidance and announced a $75M share repurchase program.
Key Financial Metrics
Key Facts
- Q4 2025 net revenue was $128.6 million, up 312% from $31.2 million in Q4 2024
- Full-year 2025 revenue was $311.7 million, with pro forma revenue of $401.3 million including Melinta
- Q4 2025 net income was $14.0 million ($0.16 diluted EPS), compared to $13.5 million ($0.20 diluted EPS) in Q4 2024
- Full-year 2025 net income was $163.1 million ($2.04 diluted EPS), versus a $17.9 million loss in 2024
- Adjusted EBITDA was $77.2 million in Q4 2025, up from $15.3 million in Q4 2024
- Company reiterated 2026 guidance: $300–$320M revenue and $100–$125M adjusted EBITDA
- Announced $75 million share repurchase program
- Cash and short-term investments totaled $148.5 million at year-end
Financial Impact
Revenue grew over 600% YoY, driven by acquisition and commercial execution. Net income swung from a $17.9M loss to $163.1M profit. Adjusted EBITDA nearly quintupled in Q4.
Risk Factors
- Revenue growth heavily influenced by the Melinta acquisition; organic growth less clear
- Q4 net income included a $42.4M tax expense tied to deferred tax assets, which may not repeat
- 2026 guidance is flat to down on revenue despite strong 2025 results, suggesting near-term moderation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250043 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | 8-K | $8.14 $7.83 | ▼ −3.87% | ▼ −2.12% | $7.19 (−11.67%) |
Aug 13, 2026 7w ago | Press Release | $8.14 $7.83 | ▼ −3.87% | ▼ −2.12% | $7.19 (−11.67%) |
Jul 1, 2026 13w ago | 8-K | $8.47 $7.19 | ▼ −15.11% | ▼ −12.93% | $7.19 (−15.11%) |
Jun 12, 2026 16w ago | Institutional Cluster | $8.74 $8.40 | ▼ −3.89% | ▼ −5.67% | $7.19 (−17.73%) |
Jun 8, 2026 16w ago | 8-K | $8.54 $8.79 | ▲ +2.93% | ▲ +1.30% | $7.19 (−15.81%) |
Jun 8, 2026 16w ago | Press Release | $8.54 $8.79 | ▲ +2.93% | ▲ +1.30% | $7.19 (−15.81%) |
May 14, 2026 20w ago | 8-K | $7.93 $8.74 | ▲ +10.21% | ▲ +11.07% | $7.19 (−9.33%) |
May 14, 2026 20w ago | Press Release | $7.93 $8.74 | ▲ +10.21% | ▲ +11.07% | $7.19 (−9.33%) |
Apr 27, 2026 22w ago | 8-K | $7.82 $8.27 | ▲ +5.75% | ▲ +0.80% | $7.19 (−8.06%) |
Apr 27, 2026 22w ago | Press Release | $7.82 $8.27 | ▲ +5.75% | ▲ +0.80% | $7.19 (−8.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access